Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials



Ahren, Bo, Atkin, Stephen L, Charpentier, Guillaume, Warren, Mark L, Wilding, John PH ORCID: 0000-0003-2839-8404, Birch, Sune, Holst, Anders Gaarsdal and Leiter, Lawrence A
(2018) Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. DIABETES OBESITY & METABOLISM, 20 (9). 2210 - 2219.

Access the full-text of this item by clicking on the Open Access link.
Item Type: Article
Uncontrolled Keywords: BMI, gastrointestinal adverse events, GLP-1 analogue, GLP-1 based therapy, nausea, type 2, vomiting, weight control, weight loss
Depositing User: Symplectic Admin
Date Deposited: 20 Jul 2018 10:20
Last Modified: 22 Jan 2021 16:10
DOI: 10.1111/dom.13353
Open Access URL: https://onlinelibrary.wiley.com/doi/epdf/10.1111/d...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3023979